Sorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Ups Its Stake and Reiterates Demands

Page 2 of 15

Page 2 of 15 – SEC Filing

CUSIP No. 83587F202 13D Page 2 of 15 Pages
1

NAMES OF REPORTING PERSONS

Wildcat Capital Management, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

2,676,193 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

2,676,193 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

2,676,193 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

6.7% (See Item 5)*

14

TYPE OF REPORTING PERSON

OO

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock (as defined herein) outstanding as of May
3, 2016, as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the
Securities and Exchange Commission (the “SEC”) on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)







Page 2 of 15